 |
3 Products |  |
155 Diseases | | 3 Products |
|
5 Trials |  |
272 News |  |
| «12 |
- ||||| VPM1002 / SAKK, Serum Institute of India
Enrollment closed, Enrollment change: Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic (clinicaltrials.gov) - Sep 30, 2020
P3, N=59, Active, not recruiting, Sponsor: Vakzine Projekt Management GmbH
Recruiting --> Active, not recruiting | N=1200 --> 59
- VPM1002 / Max Planck Institute, SAKK, Serum Institute of India
[VIRTUAL] Results of a single-arm phase I / II study with the recombinant Bacillus Calmette Guérin (BCG) VPM1002BC in patients with BCG failure - SAKK 06/14 (Lecture sessions - available at any time every day) - Sep 6, 2020 - Abstract #DGU2020DGU_100;
Recruiting --> Active, not recruiting | N=1200 --> 59 One year after starting treatment with VPM1002BC, almost half of the patients show no relapse after previous BCG failure.
- |||||| VPM1002 / SAKK, Serum Institute of India
Enrollment open: COBRA: Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity (clinicaltrials.gov) - Aug 13, 2020
P3, N=3626, Recruiting, Sponsor: University Health Network, Toronto
One year after starting treatment with VPM1002BC, almost half of the patients show no relapse after previous BCG failure. Not yet recruiting --> Recruiting
- ||| VPM1002 / Max Planck Institute, SAKK, Serum Institute of India
From revamping #BCG #VPM1002 to #COVID19 vaccines; hats off to @SerumInstIndia @adarpoonawalla https://t.co/2TcML1ojw1 @sruthijith @nytimes @gettleman (Twitter) - Aug 1, 2020
- |||||||||| VPM1002 / SAKK, Serum Institute of India
New P3 trial: COBRA: Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity (clinicaltrials.gov) - Jun 18, 2020
P3, N=3626, Not yet recruiting, Sponsor: University Health Network, Toronto
- |||||||||| VPM1002 / SAKK, Serum Institute of India
New P3 trial: Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic (clinicaltrials.gov) - Jun 17, 2020
P3, N=2038, Recruiting, Sponsor: Vakzine Projekt Management GmbH
- |||||| VPM1002 / SAKK, Serum Institute of India
Enrollment open: Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic (clinicaltrials.gov) - Jun 16, 2020
P3, N=1200, Recruiting, Sponsor: Vakzine Projekt Management GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || TMV-018 / Merck (MSD), Max Planck Institute
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker: A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract (clinicaltrials.gov) - Jun 5, 2020
P1, N=15, Not yet recruiting, Sponsor: Themis Bioscience GmbH
Not yet recruiting --> Recruiting Phase classification: P1/2 --> P1 | N=39 --> 15 | Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2021
- |||||||||| VPM1002 / SAKK, Serum Institute of India
New P3 trial: Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic (clinicaltrials.gov) - May 13, 2020
P3, N=1200, Not yet recruiting, Sponsor: Vakzine Projekt Management GmbH
- || VPM1002 / Max Planck Institute, SAKK, Serum Institute of India
Clinical, P1 data, Journal: Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. (Pubmed Central) - May 5, 2020
Plasma levels of TNFα significantly increased after treatment and blood-derived CD4+ T cells stimulated with PPD demonstrated significantly increased intracellular GM-CSF and IFN expression. The intravesical application of VPM1002BC is safe and well tolerated by patients and results in a potential Th1 weighted immune response.
- VPM1002 / Max Planck Institute, SAKK, Serum Institute of India
[VIRTUAL] Results of a phase II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin (BCG) VPM1002BC in patients with BCG failure - SAKK 06/14 () - May 2, 2020 - Abstract #EAUI2020EAU-I_306;
P1/2
One year after start of treatment, therapy with VPM100BC resulted in freedom from local bladder cancer recurrence in almost half of the patients with previous BCG failure. The treatment is safe and well tolerated.
- |||||||||| VPM1002 / SAKK, Serum Institute of India
New P3 trial: Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants (clinicaltrials.gov) - Apr 16, 2020
P3, N=6940, Not yet recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
- |||| VPM1002 / SAKK, Serum Institute of India
Trial completion date, Trial primary completion date: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence (clinicaltrials.gov) - Apr 16, 2020
P2/3, N=2000, Recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
The treatment is safe and well tolerated. Trial completion date: Nov 2019 --> May 2022 | Trial primary completion date: Aug 2019 --> Feb 2022
- ||| VPM1002 / Max Planck Institute, SAKK, Serum Institute of India
VPM1002 enhanced BCG vaccine to boost immunity against #COVID19? Trials starting in Germany hope this works! @igeorge1975 @djc795 @ZeroTLR @JessicaLuc1 @CMichaelGibson @DLBHATTMD @GreggWStone https://t.co/idzeZNjXRe (Twitter) - Apr 4, 2020
- VPM1002 / Max Planck Institute, SAKK
Results of a phase II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin (BCG) VPM1002BC in patients with BCG failure - SAKK 06/14 (Purple Area, Room Elicium 1) - Dec 23, 2019 - Abstract #EAU2020EAU_1993;
- || TMV-018 / Merck (MSD), Max Planck Institute
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker: A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract (clinicaltrials.gov) - Dec 10, 2019
P1/2, N=39, Not yet recruiting, Sponsor: Themis Bioscience GmbH
- |||| VPM1002 / SAKK, Serum Institute of India
Trial completion: Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa (clinicaltrials.gov) - Apr 18, 2018
P2, N=416, Completed, Sponsor: Serum Institute of India Pvt. Ltd.
Trial completion date: Nov 2019 --> May 2022 | Trial primary completion date: Aug 2019 --> Feb 2022 Active, not recruiting --> Completed
- | VPM1002 / SAKK, Serum Institute of India
Enrollment closed: SAKK 06/14: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 30, 2018
P1/2, N=39, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | VPM1002 / SAKK, Serum Institute of India
Enrollment open, Trial initiation date: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence (clinicaltrials.gov) - Feb 28, 2018
P2/3, N=2000, Recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Dec 2017
- | VPM1002 / SAKK, Serum Institute of India
Trial primary completion date: SAKK 06/14: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Aug 28, 2017
P1/2, N=45, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Dec 2017 Trial primary completion date: Oct 2017 --> Oct 2019
- | VPM1002 / SAKK, Serum Institute of India
New P2/3 trial: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence (clinicaltrials.gov) - May 15, 2017
P2/3, N=2000, Not yet recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
- | VPM1002 / SAKK, Serum Institute of India
Trial primary completion date: SAKK 06/14: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Feb 16, 2017
P1/2, N=45, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial primary completion date: Oct 2017 --> Oct 2019 Trial primary completion date: Dec 2016 --> Oct 2017
- ||| VPM1002 / SAKK, Serum Institute of India
Enrollment closed: Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa (clinicaltrials.gov) - Nov 23, 2016
P2, N=416, Active, not recruiting, Sponsor: Serum Institute of India Limited
Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Active, not recruiting
- VPM1002 / SAKK, Serum Institute of India
Enrollment open, Trial initiation date: SAKK 06/14: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Aug 18, 2015
P1/2, N=45, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Aug 2015
- |||| VPM1002 / SAKK, Serum Institute of India
Enrollment open: Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa (clinicaltrials.gov) - Jun 20, 2015
P2, N=416, Recruiting, Sponsor: Serum Institute of India Limited
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Aug 2015 Not yet recruiting --> Recruiting
- ||||| VPM1002 / SAKK, Serum Institute of India
New P2 trial: Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa (clinicaltrials.gov) - Mar 18, 2015
P2, N=416, Not yet recruiting, Sponsor: Serum Institute of India Limited
- VPM1002 / SAKK, Serum Institute of India
New P1/2 trial: SAKK 06/14: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Feb 26, 2015
P1/2, N=45, Not yet recruiting, Sponsor: Swiss Group for Clinical Cancer Research
- | VPM1002 / SAKK, Serum Institute of India
Trial completion: Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa (clinicaltrials.gov) - Oct 27, 2013
P2, N=48, Completed, Sponsor: Vakzine Projekt Management GmbH
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | VPM1002 / SAKK, Serum Institute of India
New P2 trial: Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa (clinicaltrials.gov) - Nov 24, 2011
P2, N=48, Completed, Sponsor: Vakzine Projekt Management GmbH
- | VPM1002 / SAKK, Serum Institute of India
Trial completion, IO biomarker: Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa (clinicaltrials.gov) - Nov 17, 2011
P1, N=24, Completed, Sponsor: Vakzine Projekt Management GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed